MetLife, Inc. filings document the regulatory record of a Delaware financial services company with NYSE-listed common stock and preferred securities, including depositary shares tied to Series E and Series F preferred stock. Recent Form 8-K reports furnish earnings releases, quarterly financial supplements, total assets under management fact sheets and Regulation FD disclosures related to variable investment income.
The filings also cover capital-structure actions such as subordinated debenture issuance and preferred stock dividend declarations. Proxy materials describe board composition, committee assignments, executive compensation and shareholder voting matters, while material-event reports record governance changes and other corporate disclosures.
MetLife, Inc. filed an 8-K reporting a news release dated September 2, 2025, that it will redeem all outstanding shares of its 3.850% fixed rate reset non‑cumulative preferred stock, Series G, on September 15, 2025. The filing notes the cover page interactive data is provided in Inline XBRL and is signed by Timothy J. Ring, Senior Vice President and Secretary.
MetLife, Inc. announced dividend declarations for multiple preferred stock series. The company declared a quarterly dividend of $0.35263005 per share on its floating-rate Series A preferred (with a $25 liquidation preference). It also declared a semi-annual dividend of $29.375 per share on Series D (5.875% fixed-to-floating, $1,000 liquidation preference), a quarterly dividend equal to $351.5625 per share on Series E (5.625%, $25,000 liquidation preference; $0.3515625 per depositary share representing 1/1,000th), a quarterly dividend equal to $296.875 per share on Series F (4.75%, $25,000 liquidation preference; $0.296875 per depositary share representing 1/1,000th), and a semi-annual dividend of $19.250 per share on Series G (3.850%, $1,000 liquidation preference). The release is attached as Exhibit 99.1 and incorporated by reference.
MetLife, Inc. filed a Form 13F Combination Report disclosing holdings managed by its investment subsidiaries. The report lists 6 table entries with a total market value of $10,392,142. The filing is signed by John McCallion, EVP, CFO and Head of MetLife Investment Management, dated 08-13-2025.
MetLife, Inc. — Schedule 13D/A (Amendment No. 102)
The Board of Directors, acting as the sole reporting person, updates its disclosure on common stock held in the MetLife Policyholder Trust formed during the 2000 demutualization. As of 31-Jul-2025 the Trust owns 108,242,821 shares, representing 16.28 % of outstanding stock. The Board possesses shared voting power over all shares but no sole voting or dispositive power; economic rights remain with policyholder beneficiaries.
The position declined by 1,161,259 shares since the 28-Apr-2025 amendment, primarily from beneficiary withdrawals, the Trust’s purchase-and-sale program and routine escheatment. No director paid consideration for the shares and no new acquisitions, sales or strategic actions are announced. Voting mechanics, beneficiary withdrawal rights and other trust provisions remain unchanged. Apart from the routine share reduction, the filing contains no material transactions or changes in corporate control intent.
MetLife has filed a Form 144 notice for the proposed sale of 1,024 shares of common stock with an aggregate market value of $81,879.04. The sale is planned to be executed through Goldman Sachs on the NYSE, with an approximate sale date of June 27, 2025.
The securities to be sold were acquired in three separate purchases during 2013:
- 31 shares from Deutsche Bank on January 31, 2013
- 902 shares from Goldman Sachs on March 13, 2013
- 91 shares from Goldman Sachs on May 15, 2013
Recent trading activity shows that related entities have sold 1,256 shares in the past three months, totaling approximately $99,076.70 in gross proceeds. The filing was made by the MetLife 401(k) Plan Trust, which maintains an affiliate discretionary manager relationship with the issuer. The company has 671,297,826 shares outstanding.